Additional Treatment Support

Additional Treatment Support

Once you have made the decision to prescribe TREMFYA™, Janssen CarePath provides support to help your patients get started and stay on track with their TREMFYA™ treatment.

Safe Returns® Disposal

Safe Returns® is a simple, safe, and convenient way for your patients to dispose of their used syringes, at no additional cost. When they sign up, they’ll receive a Safe Returns® plastic disposal container in the mail, along with simple mail-back instructions.

  • Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728) to help your patients sign up for the Safe Returns® program

Treatment Reminders

We understand how important it is for your patients to take TREMFYA™ just as you’ve prescribed.

Care4Today® Connect is a helpful medication and appointment tracking and reminder tool designed to empower users to take an active role in their own health care. This application can enable users to track key health measures, providing support and motivation in-between doctor visits in the following ways:

  • Delivers medication, medication refill, and appointment reminders
  • Enables users to record information such as blood pressure, exercise, weight, etc.
  • Users can share graphs and trends on their self-reported data with healthcare professionals
  • Provides access to medications, appointments, and self-directed adherence data in one place

Additional information is available at Care4Today.com.

Indication

TREMFYA™ is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA™ is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA™ is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA™ after physician approval and proper training.

Important Safety Information For TREMFYA

Important Safety Information

Infections
TREMFYA™ may increase the risk of infection. Treatment with TREMFYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA™ until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA™. Initiate treatment of latent TB prior to administering TREMFYA™. Monitor patients for signs and symptoms of active TB during and after TREMFYA™ treatment. Do not administer TREMFYA™ to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA™.

Adverse Reactions
Most common (≥1%) adverse reactions associated with TREMFYA™ include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA™.  Provide the Medication Guide to your patients and encourage discussion.

067010-170208